Abbott Hit with an FDA Warning Letter: A Reminder That CGM Is a Systems Engineering Challenge—Not Just a Sensor

In the CGM industry, we’re often focused on the next breakthrough : smaller sensors, longer wear time, new biomarkers like ketones.

But a recent FDA Warning Letter (CMS #722046), issued to Abbott Diabetes Care on January 23, 2026 , is a sobering reminder that technical innovation alone is not enough .

Even for a global leader with billions in CGM revenue, excellence in sensor technology means little without a flawless Quality Management System (QMS) .

When a Great Product Meets a Fragile System

The FreeStyle Libre 3 is widely regarded as an engineering achievement. Yet the FDA inspection revealed gaps—not in the idea of the product, but in how that idea was manufactured, validated, and controlled at scale .

For a device that informs life-critical dosing decisions, these are not “paperwork issues.” They are systemic risks .

What the Warning Letter Really Tells Us

The FDA cited multiple violations of 21 CFR Part 820 , all pointing to the same underlying issue: CGM is a systems engineering problem.

Key findings include:

1. Design Transfer Failures (21 CFR 820.30(h)) Design intent was not fully or consistently translated into manufacturing specifications—especially across third-party manufacturers. In complex supply chains, even small misalignments can compromise performance.

2. Gaps in Finished Device Testing (21 CFR 820.80(d)) Finished CGMs were released without accuracy testing after full assembly and sterilization. Component-level testing cannot substitute for validating the final product patients actually wear.

3. Weak Statistical Sampling (21 CFR 820.250(b)) Sampling plans lacked sound statistical justification. Without defensible statistics, confidence in large-scale production quality simply doesn’t exist.

4. Inadequate Design Validation (21 CFR 820.30(g)) The inspection raised concerns that current manufacturing controls no longer ensured the accuracy performance originally approved by regulators.

The Cost of Quality Gaps

This warning letter follows a Class I recall of nearly 3 million sensors , associated with 860 serious injuries and seven reported deaths as of early 2026.

It’s unfortunate to see a pioneer like Abbott face such scrutiny—but it also reinforces a hard truth for the entire industry:

If any one of those fails, the system fails.

What the CGM Industry Should Take Away

From our perspective at CGM Insight , this moment carries broader lessons:

• Scale does not equal safety Market leadership does not reduce regulatory expectations—it increases them.

• Quality is the product In medical devices, quality is not a support function. It is the feature that protects patients.

• Supply chains are part of the design As CGM companies scale globally, contract manufacturers must be governed with the same rigor as internal production.

A Question Worth Discussing

Building a world-class CGM doesn’t just require innovation—it demands relentless attention to the “unexciting” parts of engineering: documentation, design transfer, statistics, and process validation.

So here’s the real question for the industry:

As CGM moves toward mass-market adoption, are today’s QMS frameworks truly ready for consumer-scale volumes with medical-grade risk?